Bell Bank Reduces Stock Holdings in Bristol Myers Squibb Company $BMY

Bell Bank lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 78.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,246 shares of the biopharmaceutical company’s stock after selling 15,021 shares during the period. Bell Bank’s holdings in Bristol Myers Squibb were worth $229,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Gateway Investment Advisers LLC boosted its position in shares of Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after purchasing an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC raised its holdings in Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after purchasing an additional 30,909 shares in the last quarter. Stephens Inc. AR lifted its position in Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after buying an additional 32,476 shares during the period. Railway Pension Investments Ltd lifted its position in Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after buying an additional 40,300 shares during the period. Finally, Phoenix Financial Ltd. boosted its holdings in shares of Bristol Myers Squibb by 110.1% during the 3rd quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock valued at $4,789,000 after buying an additional 55,624 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 data for Camzyos (mavacamten) in adolescents — SCOUT‑HCM showed efficacy and safety in teens with symptomatic obstructive hypertrophic cardiomyopathy, supporting a potential label expansion and added addressable market for an established cardiovascular product. This is a clear pipeline upside that could lift long‑term revenue expectations. Bristol Myers Presents Positive SCOUT‑HCM Results
• Positive Sentiment: Supportive real‑world/switch data for Cobenfy — Phase 4/open‑label switch results indicate symptom stability and acceptable tolerability when patients transition from other oral atypical antipsychotics to Cobenfy (xanomeline + trospium). These data help the schizophrenia franchise by reducing switching risk and may aid uptake. Open‑Label Switch Study for Cobenfy
• Neutral Sentiment: Investor write‑ups and buy theses highlight valuation and dividend appeal — recent articles argue BMY’s P/E and forward metrics, plus dividend yield and upcoming ex‑dividend timing, make the stock attractive for income/value investors, which can support a base under the share price but may not trigger rapid re‑rating. Is BMY a Good Stock to Buy?
• Neutral Sentiment: Ex‑dividend timing noted — coverage points out BMY goes ex‑dividend soon, which can attract short‑term dividend seekers but has limited fundamental impact. BMY Looks Like A Good Stock, Ex‑Dividend Soon
• Neutral Sentiment: Mixed analyst sentiment — roughly 60% of covering analysts show mixed ratings even though the consensus price target (~$63) implies modest upside; this split can cap near‑term momentum until clearer fundamentals emerge. Mixed Analyst Sentiment
• Negative Sentiment: Fundamental headwinds remain from prior earnings and guidance dynamics — recent quarterly EPS missed expectations and FY‑2026 guidance is below some street forecasts, which keeps near‑term valuation under pressure and helps explain downward stock moves despite clinical positives. (Background company filings and recent results.)

Bristol Myers Squibb Price Performance

BMY opened at $58.59 on Monday. The firm has a market cap of $119.62 billion, a PE ratio of 16.98, a P/E/G ratio of 0.17 and a beta of 0.26. The stock has a 50-day moving average price of $58.82 and a 200-day moving average price of $52.27. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period last year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on BMY shares. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. UBS Group reissued a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Guggenheim reaffirmed a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Scotiabank reiterated a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.